STOCK TITAN
  1. Home
  2. News
  3. INMD

Inmode Ltd - INMD STOCK NEWS

Welcome to our dedicated news page for Inmode (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inmode's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inmode's position in the market.

News
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
Rhea-AI Summary
InMode responds to BTL's petition for Inter Partes Review of patent InMode is asserting against BTL, highlighting ongoing litigation and defense of their valuable technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
News
InMode to Report First Quarter 2024 Financial Results and Hold Conference Call May 2, 2024
Rhea-AI Summary
InMode (NASDAQ: INMD) expects Q1 revenue between $80.0M-$80.1M, pro forma revenue (including new platform pre-orders) between $95.7M-$95.8M, and decreases FY 2024 guidance to $485M-$495M. Conference call scheduled for May 2, 2024, at 8:30 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
conferences earnings
-
News
InMode to Present at Upcoming Investor Conferences and Events
Rhea-AI Summary
InMode (INMD) announces participation in upcoming investor conferences and events in April and May, featuring key executives presenting at virtual and in-person events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
conferences
News
InMode to Present at March Investor Conferences and Events
Rhea-AI Summary
InMode Ltd. (INMD) announces participation in key investor conferences in March 2024, showcasing top executives and presenting innovative medical technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
-
News
InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M
Rhea-AI Summary
InMode Ltd. (INMD) reports strong financial results for Q4 2023 and FY 2023 with record revenues, net income, and international growth. Quarterly revenue was $126.8 million, with a 20% increase in consumables and service revenue. Full-year revenue reached $492 million, with GAAP net income of $197.9 million and non-GAAP net income of $221.5 million. International revenues saw an 18% increase. The company's cash position stood at $741.6 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
earnings
-
News
InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Revenue Between $126.0M-$126.5M
Rhea-AI Summary
InMode Ltd. (INMD) is set to release its financial results for the fourth quarter and full year 2023 on February 13, 2024. The company expects revenue for the fourth quarter to be between $126.0 million and $126.5 million, with full-year revenue in the range of $491.3 million to $491.8 million. Non-GAAP earnings per diluted share for the same periods are expected to be between $0.68 and $0.69, and $2.54 to $2.55, respectively. The company anticipates a non-GAAP gross margin for the full year of 2023 to be in the range of 83% to 85%. Additionally, InMode projects revenue for the full year 2024 to be between $495 million and $505 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
conferences earnings
News
InMode Revises Full-Year 2023 Guidance
Rhea-AI Summary
InMode Ltd. (INMD) revises its full-year 2023 guidance due to stronger-than-expected headwinds from the current macroeconomic environment, resulting in a slowdown in platform sales, mainly in North America. Revenue for the full year 2023 is expected to be in the range of $485-495 million, with non-GAAP gross margin remaining at 83-85% and non-GAAP income from operations in the range of $214-218 million. Non-GAAP earnings per diluted share for the full year 2023 are expected to be in the range of $2.47-2.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.99%
Tags
none
-
News
InMode to Present at Upcoming Investor Conferences and Events
Rhea-AI Summary
InMode Ltd. (NASDAQ: INMD) will be participating in several investor conferences and events in November and December. The company will be presenting at the Jefferies London Healthcare Conference on Nov. 14 and participating in one-on-one meetings. In addition, InMode will be attending the Canaccord MTDF Investor Conference on Nov. 16 and the Mizuho Medical Device and Healthcare Services Summit on Dec. 6, both in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
conferences
-
News
InMode Reports Third Quarter 2023 Financial Results; Quarterly Revenue of $123.1M Represents 2% Year-Over-Year Growth
Rhea-AI Summary
InMode Ltd. (Nasdaq: INMD) announced its Q3 2023 financial results. The company reported quarterly revenue of $123.1 million, a 2% increase compared to Q3 2022. InMode's proprietary surgical technology platforms accounted for 83% of revenues, followed by hands-free platforms at 9% and traditional laser and non-invasive RF platforms at 8%. The company's GAAP net income was $46.5 million, while non-GAAP net income was $53.1 million. Quarterly revenues from consumables and service reached $17.9 million, a 28% increase from Q3 2022. InMode's total cash position as of September 30, 2023, was $675.8 million, including cash, cash equivalents, marketable securities, and short-term bank deposits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.35%
Tags
earnings
News
InMode Files Patent Infringement Complaint Against BTL Industries, Inc. (d/b/a BTL Aesthetics)
Rhea-AI Summary
InMode files patent infringement complaint against BTL Industries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
none
Stock INMD logo
Inmode Ltd

Nasdaq:INMD

INMD Rankings

#2145 Ranked by Market Cap
#4489 Ranked by Stock Gains
N/A Ranked by Dividends

INMD Stock Data

1.52B
75.70M
9.69%
65.69%
6.98%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
Israel
Yokne'am

About INMD

inmode offers the most exciting and effective aesthetic solutions with fractora, forma/plus, lumeccca, diolaze and bodyfx. fractora: bipolar radio-frequency fractional treatment for superior improvements in texture, wrinkles, acne scars and contraction. lumecca: broad spectrum pulsed light for rejuvenation of photo-damaged skin in a wide variety of skin types. diolaze: ultra fast diode hair removal featuring simultaneous 3pc (pre, parallel, and post cooling) technology and state of the art pulsing and power. bodyfx: non-invasive body contouring for buttocks, abdomen, flanks and thighs with a.c.e. technology